Arbutus Biopharma Corporation
NASDAQ: ABUSWarminster, US · British Columbia, Canada corporation · 45 employees on LinkedIn · 1 known investors
Find your way into Arbutus Biopharma Corporation
2,065 people in our graph share verified history with the Arbutus Biopharma Corporation team — schools, employers, funds. One of them is your warm intro.
Rebecca Jamesunlockedknows Michael J. Sofia · together at The Wharton School (overlapped)
×2knows the team · via Harvard Business School
knows the team · via Cornell
×2knows the team · via The Wharton School
knows the team · via United States Attorney's Office
×2knows the team · via Coopers & Lybrand (now PricewaterhouseCoopers)
Arbutus is a biotechnology company developing therapeutic assets and bringing them to market, with expertise spanning scientific, clinical, operational, and financial development. It focuses on drug development, partnerships, and licensing deals within the biopharma sector.
Founders & leadership
WH
William H. CollierinPresident and Chief Executive Officer2019–2023
GP
Gaston PicchioinChief Development Officer2018–2023Gaston Picchio is Chief Development Officer at Arbutus Biopharma, a biotechnology company developing therapeutic assets. He brings over two decades of experience in virology and drug development, with prior roles at Janssen R&D in which he contributed to the clinical development and approval of antivirals for HIV, hepatitis C, hepatitis B, and Zika.
MJ
Michael J. McElhaughinInterim President, CEO and Founder2024–2025
DC
David C. HastingsinChief Financial Officer2018–2025David C. Hastings is Chief Financial Officer at Arbutus Biopharma Corporation, a publicly traded biotechnology company. He has experience in capital markets, corporate finance, business development, and strategic planning at high-growth companies.
MJ
Michael J. SofiainChief Scientific OfficerMichael J. Sofia is Chief Scientific Officer at Arbutus Biopharma and has held research management positions in pharmaceutical and biotech companies, with expertise in drug discovery and early-stage development across multiple therapeutic areas. He holds 53+ patents, has published over 135 peer-reviewed articles, and led research programs that advanced multiple candidates into clinical development.
EH
Elizabeth HowardinExecutive Vice President and General Counsel, Ph.D., J.D.
LA
Lindsay AndroskiinPresident & CEO and ChairpersonLindsay Androski holds degrees from MIT (two BS), University of Chicago (JD, MBA), and is a CFA charterholder and registered patent attorney. She joined Roivant Sciences' founding team where she secured rights to over 30 drug candidates, leading to 16 biotechs, three IPOs, and five approved drugs; subsequently founded and led Roivant Social Ventures until 2025. She now serves as President, CEO, and Board Chair of Arbutus Biopharma, and as Special Counsel at Genevant Sciences managing patent litigation; earlier in her career she served as an Assistant U.S. Attorney in the Eastern District of Virginia's Cybercrime unit and led the Cyber and Data Security practice at Irell & Manella LLP.
TN
Tuan NguyeninChief Financial OfficerTuan Nguyen is Chief Financial Officer at Kinevant Sciences, a biopharmaceutical company developing therapies for unmet medical needs. He brings over 20 years of experience in finance, business development, and investment consulting within life sciences, with expertise in transaction assessment, financial modeling, and valuation analysis.
AJ
Andrew J. SunginGeneral Counsel
Board
EV
Eric VenkerBoard director
FT
Frank TortiChairman
AC
Andrew ChengBoard director
Investors · 1
Reported raises · per SEC filings
Form D private placements$15M disclosed across 1 round · 2016
▶$15MraisedDec 2021 · 1 investors · PharmaceuticalsRule 506(b)
▶$15MraisedDec 2021 · 1 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Andrew ChengDirector
- Eric VenkerDirector
- William H. CollierExecutive Officer, Director
- Gaston PicchioExecutive Officer
- Michael J. McElhaughExecutive Officer
- Frank TortiDirector
- Daniel BurgessDirector
- David C. HastingsExecutive Officer
- Michael J. SofiaExecutive Officer
- James MeyersDirector
- Elizabeth HowardExecutive Officer
- Tram TranDirector
- Richard C. HenriquesDirector
- Keith ManchesterDirector
- Offering amount
- $15M
- Amount sold
- $15M
- First sale
- Dec 2016
- Incorporated
- Corporation, British Columbia, Canada
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 4
by search overlap
Agenus43 shared keywordsAgenus is a biotechnology company developing cancer immunotherapies, including its lead investigational combination of botensilimab (an anti-CTLA-4 antibody) and balstilimab (a PD-1 inhibitor), known as BOT+BAL. It provides access to these investigational medicines for cancer patients through pathways such as clinical trials, Named Patient Programs, and compassionate-use programs across multiple countries.
Robinhood40 shared keywordsRobinhood is a financial trading platform that enables users to manage portfolios across stocks, ETFs, cryptocurrencies, options, futures, and prediction markets. The platform serves retail investors with low barriers to entry, offering portfolio management services and market insights.
Amicus Therapeutics37 shared keywordsAmicus is a rare disease biotechnology company developing medicines for people with genetically defined conditions. It operates as a wholly owned subsidiary of BioMarin Pharmaceutical Inc.
Seeking Alpha33 shared keywordsSeeking Alpha is a financial research platform offering stock analysis, market news, investment ideas, and quantitative ratings across asset classes, drawing on a large community of contributing analysts. It serves individual and professional investors seeking research and data-driven insight on stocks and markets.
Companies competing with Arbutus Biopharma Corporation for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Arbutus Biopharma Corporation do?
- Arbutus is a biotechnology company developing therapeutic assets and bringing them to market, with expertise spanning scientific, clinical, operational, and financial development. It focuses on drug development, partnerships, and licensing deals within the biopharma sector.
- Who are Arbutus Biopharma Corporation's investors?
- Arbutus Biopharma Corporation's investors include Foresite Capital.
- How much funding has Arbutus Biopharma Corporation raised?
- Arbutus Biopharma Corporation has disclosed $15M raised across 1 round.
- Where is Arbutus Biopharma Corporation headquartered?
- Arbutus Biopharma Corporation is headquartered in Warminster, US.